World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT03113318
Date of registration: 10/04/2017
Prospective Registration: No
Primary sponsor: Rigshospitalet, Denmark
Public title: Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer
Scientific title: Total Mediastinal Lymph Node Dissection in Pulmonary Metastasectomy From Colorectal Cancer - a Randomized, Controlled Trial
Date of first enrolment: October 2015
Target sample size: 200
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT03113318
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
Denmark
Contacts
Name:     Kåre Hornbech, MD
Address: 
Telephone: +4535451212
Email: kaare.hornbech.01@regionh.dk
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age > 18 years

- Able to give informed consent

- Willing to be randomized

Exclusion Criteria:

- Previous mediastinal lymphadenectomy

- Previous pulmonary metastasectomy

- Evidence of other metastasetic disease

- Primary tumor is not under control

- Five metastases or more

- If final histologic examination of the resected lung lesion(s) reveals other histology
than colorectal metastasis



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Neoplasm Metastasis
Lung Neoplasms
Colorectal Cancer
Intervention(s)
Procedure: Total mediastinal lymph node dissection and pulmonary metastasectomy
Procedure: Only pulmonary metastasectomy
Primary Outcome(s)
5-year overall survival [Time Frame: 7-8 years]
Secondary Outcome(s)
1-, 3-, 5-year disease free survival [Time Frame: 7-8 years]
1-year overall survival [Time Frame: 3-4 years]
3-year overall survival [Time Frame: 4-5 years]
Number of lymph nodes removed [Time Frame: 2-3 years]
30- day morbidity [Time Frame: 2-3 years]
30-day mortality [Time Frame: 2-3 years]
Secondary ID(s)
Khornbech
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
M.D. Anderson Cancer Center
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history